

Patient generated data


Patients would generate different data all along the medicines' life-cycle

François Houÿez

Real-time feedback – COVID-19, France

Renaloo, social network of patients with kidney transplant or dialysis

- 22 June to 12 July 2020: 2,030 respondents / 10,000 members
 - Only 33% had a direct contact with nephrologist during the 2-month lockdown
 - 25% of those on renal transplant waiting list: not informed of the suspension of adult kidney transplantation
- 4 to 23 February 2021: 2,300 respondents
 - 96% were or wished to be vaccinated (versus 64% in general population at that time)
- July 2021: 2,389 respondents
 - 85.4% dialysed and 87.8% transplanted got at least one vaccine dose
- October 2021
 - 2 months after Ronapreve® CU started, despite "DGS urgent" only 2% of 57,000 patients (CU indication) were treated
- March 2022
 - > 75% of kidney transplant patients inadequately protected by vaccination still not received Evusheld® prophylaxis (CU opened December 2021)





Reflection paper on patient experience data

Table of contents

1. Introduction	3
0 1.1. Background	3
11 1.2. Problem statement	3
12 1.3. Scope	4
13 2. Discussion	4
14 2.1. The EU regulatory approach to patient experience data	4
15 2.1.1. Patient experience data	4
16 2.1.2. The Agency's view on patient experience data	5
17 2.2. Use and value of patient experience data along the medicine's lifecycle	6
18 2.3. Types of patient experience data	8
19 2.3.1. Patient-reported outcomes	8
20 2.3.2. Patient preference studies	9
21 2.3.3. Data obtained through patient engagement activities	11
22 2.4. Sources of patient experience data	13
23 2.4.1. Patient experience data collected in clinical trials	14
24 2.4.2. Real-world data as a source of patient experience data	14
25 2.4.3. Safety surveillance systems	15
26 2.4.4. Other potential sources of patient experience data	15
27 2.5. Considerations for systematic implementation of patient experience data	15
28 2.5.1. Data quality	15
29 2.5.2. Representativeness	16
30 2.5.3. Study design	16
31 2.5.4. Data collection methods and tools	16
32 2.5.5. Challenges related to the use of PROs	17
33 2.5.6. Participant burden	17
34 2.5.7. Training and capacity building	17
35 2.5.8. Language	17
36 2.5.9. Perceived lack of value	18
37 2.5.10. Transparency on the use of PED in regulatory assessment	18
38 2.5.11. Global alignment on patient experience data	18
39 3. Conclusions	19
40 4. References	
41 5. Glossary	

Call to Action!

Express your views on the Reflection
Paper on Patient Experience Data
Consultation until 31 January 2026

